The Top Antitrust Conduct Cases Of 2019: Midyear Report
The world's dominant chipmaker saw part of its business model deemed illegal, the Federal Trade Commission added a new kind of generic drug patent settlement to the list of banned deals,...To view the full article, register now.
Already a subscriber? Click here to view full article